NCT02523014 2026-04-07
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
Clinical Trials
16 trialsNCT03801369 2026-02-25
AMTEC IIT: Phase 2 Multiarm Study in TNBC
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT07426822 2026-02-24
SAFE-CAP
Yale University
Phase 2 Not yet recruiting
NCT05826964 2026-01-13
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
University of Miami
Phase 2 Active not recruiting
NCT06613516 2025-12-24
CaptAin
Imperial College London
Phase 2 Withdrawn
NCT02664935 2025-05-21
National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer
University of Birmingham
Phase 2 Active not recruiting
NCT06607757 2025-04-02
Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer
GBG Forschungs GmbH
Phase 2 Recruiting
NCT02423603 2025-03-10
PAKT
Queen Mary University of London
Phase 2 Completed
NCT02299999 2025-01-15
SAFIR02_Breast
UNICANCER
Phase 2 Active not recruiting
NCT05720260 2024-06-10
Immunotherapy, Hormone Therapy, and AKT Inhibitor for Premenopausal ER Positive MBC
National Taiwan University Hospital
Phase 2 Recruiting
NCT02117167 2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2 Completed
NCT02576444 2022-12-28
OLAPCO
Yale University
Phase 2 Terminated
NCT02451956 2019-12-30
Study of AZD5363 in Combination With Paclitaxel, in Advanced Gastric Adenocarcinoma Patients Harboring PIK3CA Mutation and/or PIK3CA Amplification as a Second-line Chemotherapy
Samsung Medical Center
Phase 2 Completed
NCT03182634 2019-01-22
plasmaMATCH
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT02525068 2018-08-08
RE-AKT
Institute of Cancer Research, United Kingdom
Phase 2 Unknown
NCT02077569 2017-05-04
STAKT
University of Nottingham
Phase 2 Completed